Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib
Publication
, Conference
Gupta, V; Yacoub, A; Fazal, S; Miller, C; Verstovsek, S; Mesa, R; Harrison, C; Barosi, G; Kiladjian, J-J; Mattison, R; Rein, L; Reeves, B ...
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2020
Duke Scholars
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2020
Volume
20
Start / End Page
S331 / S332
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Gupta, V., Yacoub, A., Fazal, S., Miller, C., Verstovsek, S., Mesa, R., … Talpaz, M. (2020). Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 20, pp. S331–S332).
Gupta, Vikas, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, Claire Harrison, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20:S331–32, 2020.
Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, et al. Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S331–2.
Gupta, Vikas, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 20, 2020, pp. S331–32.
Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, Harrison C, Barosi G, Kiladjian J-J, Mattison R, Rein L, Reeves B, Oh S, Parameswaran V, Deeg J, Rose S, Chia V, Wang T, Talpaz M. Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S331–S332.
Published In
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
EISSN
2152-2669
ISSN
2152-2650
Publication Date
2020
Volume
20
Start / End Page
S331 / S332
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3201 Cardiovascular medicine and haematology
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences